

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 152 765 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
13.10.2004 Bulletin 2004/42

(51) Int Cl.7: **A61K 31/70**, C07H 1/00,
C07H 17/08

(21) Application number: **99965069.0**

(86) International application number:
PCT/US1999/028368

(22) Date of filing: **30.11.1999**

(87) International publication number:
WO 2000/032203 (08.06.2000 Gazette 2000/23)

(54) **ETHANOLATE OF AZITHROMYCIN, PROCESS FOR MANUFACTURE, AND PHARMACEUTICAL COMPOSITIONS THEREOF**

ETHANOLATE DES AZITHROMYCIN, HERSTELLUNGSVERFAHREN UND DEREN
PHARMAZEUTISCHE ZUSAMMENSTELLUNGEN

ETHANOLATE D'AZITHROMYCINE, PROCEDE DE FABRICATION, ET COMPOSITIONS
PHARMACEUTIQUES EN CONTENANT

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

(30) Priority: **30.11.1998 US 110298 P**

(43) Date of publication of application:
14.11.2001 Bulletin 2001/46

(60) Divisional application:
04014455.2

(73) Proprietor: **TEVA PHARMACEUTICAL
INDUSTRIES LTD.
49131 Petah Tiqva (IL)**

(72) Inventors:
• **SINGER, Claude**
Kfar Sava (IL)
• **ARONHIME, Judith**
Rehovot (IL)

(74) Representative: **Schlich, George William et al**
Mathys & Squire
100 Gray's Inn Road
London WC1X 8AL (GB)

(56) References cited:
EP-A- 0 307 128 EP-A- 0 984 020
WO-A1-89/00576 US-A- 4 474 768

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 152 765 B1


Description

FIELD OF THE INVENTION

[0001] This invention relates to a new ethanolate of azithromycin, processes for its manufacture, and pharmaceutical compositions containing the new ethanolate.

BACKGROUND OF THE INVENTION

[0002] Azithromycin, 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, having the formula



is a semi-synthetic macrolide antibiotic related to erythromycin A, useful for treating infections caused by susceptible microorganisms. This invention provides a new non-hygroscopic form of azithromycin, processes for its manufacture, and pharmaceutical compositions containing it.

[0003] Azithromycin may be made by methods described in U.S. Patent Nos. 4,517,359 and 4,474,768. According to European Patent Application EP 298,650, the azithromycin obtained by these methods is a hygroscopic monohydrate. Because of its hygroscopic nature, this monohydrate is difficult to prepare and maintain in a form having a constant, reproducible water-content, and is particularly difficult to handle during formulation. EP 298,650 describes a dehydrate form of azithromycin that is less hygroscopic than the previously known monohydrate. The method described in EP 298,650 for making the dehydrate form is by crystallization from tetrahydrofuran, hexane and water.

[0004] Chinese Patent Application CN 1,093,370, describes an azithromycin crystal having water content of 4-6%. This form of azithromycin is stated as being less hygroscopic than the dehydrate described in EP 298,650. The method disclosed in CN 1,093,370 for making the described form of azithromycin is by crystallization from acetone and water.

SUMMARY OF INVENTION

[0005] The present invention provides a new ethanolate of azithromycin that is less hygroscopic than azithromycin monohydrate. The new ethanolate has an ethanol content of about 1.5% to about 3% and a water content of about 2% to about 4%.

[0006] The present invention also provides a method of making an ethanolate of azithromycin, comprising the steps of:

- dissolving azithromycin in ethanol,
- adding water to the azithromycin solution such that crystallization of the azithromycin begins and a suspension is formed, and
- isolating the crystals of azithromycin.

[0007] The present invention further provides a pharmaceutical composition comprising a therapeutic amount of an ethanolate of azithromycin in accordance with the present invention and a pharmaceutically acceptable carrier.

BRIEF DESCRIPTION OF THE DRAWINGS

[0008]

Figure 1 is a comparison of hygroscopicity of the azithromycin ethanolate of the present invention and azithromycin monohydrate over a range of relative humidity, based upon data provided in EP 298,650.

Figure 2 is a characteristic powder X-ray diffraction pattern of the azithromycin ethanolate of the present invention.

DETAILED DESCRIPTION OF THE INVENTION

[0009] The present invention discloses a new ethanolate of azithromycin that is less hygroscopic than the prior art monohydrate, and has an ethanol content of about 1.5 to about 3% and water content of about 2 to about 4%. Preferably the ethanol content is between about 1.5% and about 2.5%. Preferably the water content is between about 2.5% and about 3.5%. A comparison of the hygroscopicity of the ethanolate of the present invention and azithromycin monohydrate can be found at Figure 1.

[0010] The process for manufacture of azithromycin ethanolate of the present invention utilizes the fact that water is a poorer solvent for azithromycin than ethanol, so that the addition of water to a solution of azithromycin in ethanol causes crystallization. Second, heating a solution of azithromycin in ethanol in the presence of water promotes crystallization.

[0011] In accordance with the process aspects of the invention, azithromycin is dissolved in absolute ethanol, in a ratio of about 2.5:1 (ethanol:azithromycin by weight) at a temperature of between about 10°C and about 80°C, preferably at about 20° to about 30°C. A minimal amount of water is added, i.e. an amount no greater than 20% (by weight versus ethanol), preferably about 6 to about 16%. The solution is heated slowly at a constant temperature gradient over a first time interval of about 2 to about 18 hours, preferably about 3 to about 8 hours, reaching a maximum temperature of about 30 to about 80°C and preferably about 40 to about 60°C at the end of the first time interval. Crystallization appears to begin in the temperature range of about 30-45°C. During the first time interval, the water content of the solution is gradually increased, but to a concentration of no more than about 50%.

[0012] At the end of the first time interval, the resulting suspension is maintained at the maximum temperature for a second time interval of about 1 to about 18 hours, preferably about 1 to about 4 hours. During the second time interval, additional water is added to complete the crystallization process.

[0013] At the end of the second time interval, the suspension is cooled using a constant temperature gradient over a third time interval of about 1 to about 18 hours, preferably about 2 to about 4 hours, reaching a final temperature of about 20°C. The resulting precipitate is collected by filtration and dried to constant weight. Table 1 shows the water content of the new azithromycin ethanolate using Karl Fisher analysis and ethanol content using gas chromatography.

Table 1.

Ethanol and Water Content of Azithromycin Ethanolate		
Batch	Ethanol Content (gas chromatography)	Water Content (Karl- Fischer)
	% w/w (weight/weight)	% w/w
A	2.2	3.24
B	2.3	2.46
C	2.2	2.71
D	2.3	2.77
E	2.2	3.28
F	1.52	2.70
G	1.7	3.40

[0014] In accordance with the present invention, the new ethanolate of azithromycin may be prepared as pharmaceutical compositions that are particularly useful for the treatment of infections caused by susceptible microorganisms. Such compositions comprise the new ethanolate of azithromycin with pharmaceutically acceptable carriers and/or excipients.

[0015] For example, these compositions may be prepared as medicines to be administered orally, parenterally, rectally, transdermally, buccally, or nasally. Suitable forms for oral administration include tablets, compressed or coated

pills, dragees, sachets of powder for reconstitution, hard or gelatin capsules, sub-lingual tablets, syrups and suspensions. Suitable forms for parenteral administration include an aqueous or nonaqueous solution or emulsion, while for rectal administration suitable forms include suppositories with hydrophilic or hydrophobic vehicles. For topical application the invention provides ointments or aerosol formulations known in the art; for transdermal delivery there are provided suitable delivery systems as known in the art. For nasal delivery there are provided suitable aerosol delivery systems known in the art.

Experimental Details

[0016] Hygroscopicity profiles were obtained by maintaining samples in controlled humidity chambers for a period of two weeks, followed by Karl Fisher analysis of water content.

[0017] Gas chromatograms were obtained using a Hewlett-Packard 5890 gas chromatograph.

[0018] Powder x-ray diffraction patterns were obtained by methods known in the art using a Philips X-Ray powder diffractometer, Goniometer model 1050/70 at a scanning speed of 2° per minute, with a Cu radiation of $\lambda = 1.5418 \text{ \AA}$.

[0019] This invention will be better understood from the Example that follows. However, the examples illustrate, but do not limit, the invention. Those skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims that follow thereafter.

EXAMPLE

Preparation of Azithromycin Ethanolate.

[0020] Ten g of azithromycin crude was introduced into a 0.25 liter three-necked flat flanged jacketed vessel equipped with a mechanical stirrer, a condenser and thermometer and containing 30 ml of absolute ethanol at 20°C. Three ml of water at 20°C were added and the solution was heated at a constant temperature gradient so as to reach 55°C after 4 hours. Between 35°C and 55°C, additional water having a total volume of 11 ml was slowly added at regular time intervals. When 55°C was reached, the resulting suspension was maintained at this temperature for 2 hours, during which an additional 49 mL of water was added. The suspension was then cooled from 55°C to 20°C over 2 hours. The precipitate was filtered. After drying, 9 g of azithromycin ethanolate were obtained.

[0021] Although certain presently preferred embodiments of the invention have been described herein, it will be apparent to those skilled in the art to which the invention pertains that variations and modifications of the described embodiments may be made without departing from the scope of the invention. Accordingly, it is intended that the invention be limited only to the extent required by the appended claims and the applicable rules of law.

Claims

1. An ethanolate of azithromycin having an ethanol content of about 1.5% to about 3%.
2. The ethanolate of claim 1, having a water content of about 2% to about 4%.
3. The ethanolate of claim 2, wherein the water content is between about 2.5% and about 3.5%.
4. The ethanolate of claim 1, wherein the ethanol content is about 1.5% to about 2.5%.
5. The ethanolate of claim 4, wherein the water content is about 2% to about 4%.
6. The ethanolate of claim 5, wherein the water content is between about 1.5% and about 2.5%.
7. An ethanolate of azithromycin that is **characterized by** a powder x-ray diffraction pattern substantially as depicted in Figure 2.
8. A method of making an ethanolate of azithromycin of claim 1, comprising the steps of:
 - dissolving azithromycin in ethanol,
 - adding water to the azithromycin solution such that crystallization of the azithromycin begins and a suspension is formed, and
 - isolating the crystals of azithromycin.

9. The method of claim 8, further comprising the step of maintaining the suspension at a temperature from about 30° to about 80°C.
10. The method of claim 9 wherein additional water is added to the suspension, and the suspension is held at a temperature from about 30° to about 80°C for about 1 to about 18 hours.
11. The method of claim 10, wherein the suspension is cooled to about 20°C prior to isolating the crystals of azithromycin.
12. The method of claim 8, wherein the ethanolate has an ethanol content of about 1.5% to about 3%.
13. The method of claim 12, wherein the ethanolate has a water content of about 2% to about 4%.
14. The method of claim 8, wherein the ethanolate is **characterized by** a powder x-ray diffraction pattern substantially as depicted in Figure 2.
15. A pharmaceutical composition comprising a therapeutically effective amount of the ethanolate of the claim 1 and a pharmaceutically acceptable carrier.

Patentansprüche

1. Ethanolat des Azithromycins mit einem Ethanolgehalt von etwa 1,5 % bis etwa 3 %.
2. Ethanolat nach Anspruch 1 mit einem Wassergehalt von etwa 2 % bis etwa 4 %.
3. Ethanolat nach Anspruch 2, worin der Wassergehalt zwischen etwa 2,5 % und etwa 3,5 % beträgt.
4. Ethanolat nach Anspruch 1, worin der Ethanolgehalt etwa 1,5 bis etwa 2,5 % beträgt.
5. Ethanolat nach Anspruch 4, worin der Wassergehalt etwa 2 % bis etwa 4 % beträgt.
6. Ethanolat nach Anspruch 5, worin der Wassergehalt zwischen etwa 1,5 % und etwa 2,5 % beträgt.
7. Ethanolat des Azithromycins, das durch ein Pulver-Röntgenbeugungsmuster gekennzeichnet ist, im Wesentlichen wie in Figur 2 gezeigt.
8. Verfahren zur Herstellung eines Ethanolats des Azithromycins nach Anspruch 1, umfassend die Schritte:
Lösen von Azithromycin in Ethanol,
Zusetzen von Wasser zur Azithromycinlösung, so dass eine Kristallisation des Azithromycins beginnt und eine Suspension gebildet wird, und
Isolieren der Kristalle des Azithromycins.
9. Verfahren nach Anspruch 8, zusätzlich umfassend den Schritt des Haltens der Suspension bei einer Temperatur von etwa 30° C bis etwa 84° C.
10. Verfahren nach Anspruch 9, worin zusätzliches Wasser zur Suspension zugesetzt wird und man die Suspension für etwa 1 bis etwa 18 Stunden bei einer Temperatur von etwa 30° C bis etwa 80° C hält.
11. Verfahren nach Anspruch 10, worin die Suspension vor dem Isolieren der Kristalle des Azithromycins auf etwa 20° C gekühlt wird.
12. Verfahren nach Anspruch 8, worin das Ethanolat einen Ethanolgehalt von etwa 1,5 % bis etwa 3 % aufweist.
13. Verfahren nach Anspruch 12, worin das Ethanolat einen Wassergehalt von etwa 2 % bis etwa 4 % hat.
14. Verfahren nach Anspruch 8, worin das Ethanolat durch ein Pulver-Röntgenbeugungsmuster gekennzeichnet ist,

im Wesentlichen wie in Figur 2 gezeigt.

15. Pharmazeutische Zusammensetzung, umfassend eine therapeutisch wirksame Menge des Ethanolats nach Anspruch 1 und einen pharmazeutisch annehmbaren Träger.

Revendications

1. Ethanolate d'azithromycine ayant une teneur en éthanol d'environ 1,5 % à environ 3 %.
2. Ethanolate selon la revendication 1, ayant une teneur en eau d'environ 2 % à environ 4 %.
3. Ethanolate selon la revendication 2, dans lequel la teneur en eau est comprise entre environ 2,5 % et environ 3,5 %.
4. Ethanolate selon la revendication 1, dans lequel la teneur en éthanol est d'environ 1,5 % à environ 2,5 %.
5. Ethanolate selon la revendication 4, dans lequel la teneur en eau est d'environ 2 % à environ 4 %.
6. Ethanolate selon la revendication 5, dans lequel la teneur en eau est comprise entre environ 1,5 % et environ 2,5 %.
7. Ethanolate d'azithromycine qui est **caractérisé par** un profil de diffraction aux rayons X des poudres sensiblement tel que décrit sur la Figure 2.
8. Procédé pour préparer un éthanolate d'azithromycine selon la revendication 1, comprenant les étapes de :
 - dissolution de l'azithromycine dans de l'éthanol,
 - addition d'eau à la solution d'azithromycine de façon que la cristallisation de l'azithromycine commence et qu'une suspension soit formée, et
 - isolation des cristaux d'azithromycine.
9. Procédé selon la revendication 8, comprenant en outre l'étape de maintien de la suspension à une température d'environ 30 à environ 80°C.
10. Procédé selon la revendication 9, dans lequel de l'eau additionnelle est ajoutée à la suspension, et la suspension est maintenue à une température d'environ 30° à environ 80°C pendant environ 1 à environ 18 heures.
11. Procédé selon la revendication 10, dans lequel la suspension est refroidie à environ 20°C avant l'isolation des cristaux d'azithromycine.
12. Procédé selon la revendication 8, dans lequel l'éthanolate a une teneur en éthanol d'environ 1,5 % à environ 3 %.
13. Procédé selon la revendication 12, dans lequel l'éthanolate a une teneur en eau d'environ 2 % à environ 4 %.
14. Procédé selon la revendication 8, dans lequel l'éthanolate est **caractérisé par** un profil de diffraction aux rayons X des poudres sensiblement tel que décrit sur la Figure 2.
15. Composition pharmaceutique comprenant une quantité efficace, du point de vue thérapeutique, de l'éthanolate de la revendication 1, et un véhicule acceptable en pharmacie.




FIG. 1




FIG. 2

REGISTER ENTRY FOR EP1152765

European Application No EP99965069.0 filing date 30.11.1999

Priority claimed:

30.11.1998 in United States of America - doc: 110298P

PCT EUROPEAN PHASE

PCT Application PCT/US1999/028368 Publication No WO2000/032203 on
08.06.2000

Designated States AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

Title ETHANOLATE OF AZITHROMYCIN, PROCESS FOR MANUFACTURE, AND PHARMACEUTICAL
COMPOSITIONS THEREOF

Applicant/Proprietor

TEVA PHARMACEUTICAL INDUSTRIES LTD., 5 Basel Street, P.O. Box 3190, 49131
Petah Tiqva, Israel [ADP No. 61685327003]

Inventors

CLAUDE SINGER, 8 David Elazar Street, Kfar Sava, Israel
[ADP No. 71110852001]

JUDITH ARONHIME, 8 Hava Lutzky Street, Rehovot, Israel
[ADP No. 71110860001]

Classified to

A61K C07H

Address for Service

MATHYS & SQUIRE, 100 Grays Inn Road, LONDON, WC1X 8AL, United Kingdom
[ADP No. 00001081001]

EPO Representative

GEORGE WILLIAM SCHLICH, Mathys & Squire, 100 Gray's Inn Road, London WC1X
8AL, United Kingdom [ADP No. 67446682001]

Publication No EP1152765 dated 14.11.2001

Publication in English

Examination requested 28.05.2001

Patent Granted with effect from 13.10.2004 (Section 25(1)) with title
ETHANOLATE OF AZITHROMYCIN, PROCESS FOR MANUFACTURE, AND PHARMACEUTICAL
COMPOSITIONS THEREOF

02.09.2004 MATHYS & SQUIRE, 100 Grays Inn Road, LONDON, WC1X 8AL, United
Kingdom [ADP No. 00001081001]

registered as address for service

Entry Type 8.11 Staff ID. PHE1 Auth ID. F51

REGISTER ENTRY FOR EP1152765 (Cont.)

TIMED: 09/03/05 08:36:13

PAGE: 2

11.10.2004 Notification of change of Address For Service name and address of
MATHYS & SQUIRE, 100 Grays Inn Road, LONDON, WC1X 8AL, United
Kingdom [ADP No. 00001081001]
to

D YOUNG & CO, 120 Holborn, LONDON, EC1N 2DY, United Kingdom
[ADP No. 00000059006]

dated 06.10.2004. Official evidence filed on EP REG MAIN
Entry Type 7.1 Staff ID. NKNO Auth ID. F51

**** END OF REGISTER ENTRY ****

OA80-01
EP

OPTICS - PATENTS

09/03/05 08:36:24
PAGE: 1

RENEWAL DETAILS

PUBLICATION NUMBER EP1152765

PROPRIETOR(S)

TEVA PHARMACEUTICAL INDUSTRIES LTD., 5 Basel Street, P.O. Box 3190,
49131 Petah Tiqva, Israel

DATE FILED 30.11.1999

DATE GRANTED 13.10.2004

DATE NEXT RENEWAL DUE 30.11.2005

DATE NOT IN FORCE

DATE OF LAST RENEWAL 22.11.2004

YEAR OF LAST RENEWAL 06

STATUS PATENT IN FORCE

**** END OF REPORT ****